Oncoinvent As | MedPath

Radspherin Shows Promise in Colorectal Cancer Peritoneal Metastases: Phase 1/2a Data

7 months ago

• Phase 1/2a study of Radspherin® demonstrates encouraging safety and efficacy in colorectal cancer patients with peritoneal metastases. • At 18 months, no peritoneal recurrences were observed in patients receiving the recommended dose of Radspherin® after cytoreductive surgery and HIPEC. • The study highlights the potential of Radspherin® as a novel treatment option for peritoneal metastases, addressing an urgent unmet need. • Further clinical evaluation is warranted based on the promising efficacy signal observed in the RAD-18-002 study.